Piramal Pharma Ltd

Piramal Pharma Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 August 2026, providing investors with the latest insights into the company’s performance and outlook.

From a 52-week low of Rs 132.50 to a fresh high of Rs 212.45, Piramal Pharma Ltd has delivered an 11.5% return over the past year, comfortably outpacing the Sensex’s decline of 2.3%. This milestone caps a four-day winning streak that has propelled the stock above all major moving averages, signalling robust price momentum.

Piramal Pharma Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. Despite a mixed bag of monthly and weekly technical indicators, the stock’s recent price action and moving averages suggest an improving outlook for this small-cap pharmaceutical player, even as its MarketsMOJO Mojo Grade was downgraded to Sell from Hold on 16 Jul 2026.

Piramal Pharma Ltd has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish trend as of early August 2026. Despite a recent upgrade in daily moving averages and weekly MACD signals, monthly indicators present a more cautious outlook, reflecting a complex interplay of bullish and bearish forces in the Pharmaceuticals & Biotechnology sector.

Piramal Pharma Ltd has experienced a notable shift in its valuation parameters, moving from a fair to an expensive rating, prompting a downgrade in its Mojo Grade from Hold to Sell. Despite recent positive price momentum, the company’s elevated price-to-earnings and price-to-book ratios relative to historical and peer averages raise questions about its current price attractiveness for investors.

Piramal Pharma Ltd has recently experienced a downgrade in its quality grade from 'Average' to 'Below Average' as of 16 July 2026, reflecting a notable deterioration in key business fundamentals. This shift accompanies a downgrade in the Mojo Grade from Hold to Sell, signalling growing concerns over the company’s operational efficiency, profitability, and capital structure amid a challenging pharmaceutical sector landscape.

Piramal Pharma Ltd has experienced a marked deterioration in its financial performance in the quarter ended June 2026, with key profitability metrics turning negative and operational efficiency weakening. Despite this, the stock has delivered strong short-term returns, outperforming the broader Sensex, though longer-term gains remain modest.

Piramal Pharma Ltd (PPLPHARMA) has emerged as one of the most actively traded stocks on 30 July 2026, registering a remarkable surge in volume alongside a steady price appreciation. The stock’s sustained six-day rally, combined with rising investor participation and favourable technical signals, underscores growing market confidence in this small-cap pharmaceutical player.

Piramal Pharma Ltd. reported a consolidated net loss of ₹69.39 crores for Q1 FY27, marking a marginal improvement from the ₹81.70 crore loss in Q1 FY26, though losses widened significantly on a sequential basis. The ₹26,314-crore pharmaceutical company continues to grapple with profitability challenges despite posting 17.39% year-on-year revenue growth to ₹2,269.92 crores, as operating margins remain under pressure and elevated interest costs weigh on the bottom line.

Piramal Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 July 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 28 July 2026, providing investors with an up-to-date view of the stock’s fundamentals and market performance.

Piramal Pharma Ltd has demonstrated a notable shift in its technical momentum, moving from a mildly bullish to a bullish stance, supported by a range of technical indicators including MACD, RSI, Bollinger Bands, and moving averages. This transition accompanies a strong price performance, with the stock surging 6.02% on 28 Jul 2026, signalling renewed investor confidence amid a challenging pharmaceutical sector backdrop.

Piramal Pharma Ltd has seen its investment rating upgraded from Sell to Hold as of 16 July 2026, reflecting a nuanced improvement across technical indicators, valuation metrics, and financial trends despite ongoing challenges in profitability and debt servicing. The company’s stock price has gained 1.75% on the day, signalling renewed investor interest amid a complex market backdrop.

Piramal Pharma Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish outlook. This change is underscored by a combination of mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, reflecting a nuanced market sentiment for the pharmaceutical small-cap stock.

The 50-day moving average for Piramal Pharma Ltd has crossed above the 200-day moving average, creating a golden cross on 16 Jul 2026. While this technical event often signals a shift towards bullish momentum, the broader technical and fundamental context presents a more nuanced picture that merits careful analysis.

Piramal Pharma Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance as of mid-July 2026. Despite some bullish weekly indicators, the overall technical landscape presents a complex picture, with mixed signals from key momentum and trend-following indicators such as MACD, RSI, Bollinger Bands, and moving averages. This nuanced technical scenario coincides with a recent downgrade in the company’s Mojo Grade from Hold to Sell, reflecting growing caution among market participants.